Abstract: A process extends manufacturing execution system (MES) functionalities in a domain having MES lineage contextualized entities (MLCEs) and commands. The process includes selecting a command implementing the functionality to be extended; contextualizing the command with a MLCE to obtain an entity contextualized command (ECC); extending the MLCE and the ECC, to obtain an extended MLCE (EMLCE) and an extended ECC (EECC); registering in the routing system a first and second handler of the command in association with the lineage of the MLCE and the EMLCE; and communicating between domains by delivering message(s) including a name of the command and the MLCE or the EMLCE, the routing system selecting the first or the second handler, for executing the functionality or the extended functionality, based on a mapping between the lineage registered for the first or the second handlers in the routing system, and a lineage derived from the message.

Abstract: A process extends manufacturing execution system (MES) functionalities in a domain having MES lineage contextualized entities (MLCEs) and commands. The process includes selecting a command implementing the functionality to be extended; contextualizing the command with a MLCE to obtain an entity contextualized command (ECC); extending the MLCE and the ECC, to obtain an extended MLCE (EMLCE) and an extended ECC (EECC); registering in the routing system a first and second handler of the command in association with the lineage of the MLCE and the EMLCE; and communicating between domains by delivering message(s) including a name of the command and the MLCE or the EMLCE, the routing system selecting the first or the second handler, for executing the functionality or the extended functionality, based on a mapping between the lineage registered for the first or the second handlers in the routing system, and a lineage derived from the message.

Abstract: 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds of the general formula (I): processes for the preparation of said compounds, pharmaceutical compositions containing said compounds and the use of said compounds for the manufacture of medicaments suitable for the treatment of cancerous diseases.

Abstract: The present invention relates to 2-alkoxy and 2-aryloxyestrogen compounds, and the intermediate compounds prepared during the preparation thereof, which intermediate compounds are useful intermediates in the preparation of certain physiologically active compounds.

Abstract: The present invention relates to a method for preparing 2-alkoxy and 2-aryloxyestrogen compounds, and the intermediate compounds prepared during the use of this method, which intermediate compounds are useful intermediates in the preparation of certain physiologically active compounds.

Abstract: 13-substituted 5,6-dihydrodibenzo[a,g]quinolizinium salt compounds of the general formula (I): processes for the preparation of said compounds, pharmaceutical compositions containing said compounds and the use of said compounds for the manufacture of medicaments suitable for the treatment of cancerous diseases.

Abstract: The present invention relates to a method for preparing 2-alkoxy and 2-aryloxyestrogen compounds, and the intermediate compounds prepared during the use of this method, which intermediate compounds are useful intermediates in the preparation of certain physiologically active compounds.

Abstract: A process for the total synthesis of Distamycin, and synthetic poly-(4 aminopyrrole-2-carboxamide) congeners thereof, using 1-methyl-4-forinylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate, is provided. The process finds application for both in solution and solid support synthetic technologies.

Abstract: A process for the total synthesis of Distamycin, and synthetic poly-(4aminopyrrole-2-carboxamide) congeners thereof, using 1-methyl-4-forinylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate, is provided. The process finds application for both in solution and solid support synthetic technologies.

Abstract: Use of distamycin, analogues and/or derivatives thereof in the manufacture of a pharmaceutical composition having activity against endoparasitosis in animals.

Abstract: The present invention refers to tachykinins antagonists of general formula (I) ##STR1## their preparation and pharmaceutical compositions containing them.

Abstract: 8-fluoro-anthracyclines of formula (I) have anti-tumor activity. ##STR1## wherein: R is chosen in the group consisting of H, OH, OR.sub.4 wherein R.sub.4 is chosen in the group consisting of CHO, COCH.sub.3, acyl derivative of a carboxylic acid containing up to 6 carbon atoms;R.sub.1 is chosen in the group consisting of: H, OH, OCH.sub.3 ;R.sub.2 is chosen in the group consisting of: H, OH, NH.sub.2R.sub.3 is chosen in the group consisting of: H, OH, NH.sub.2, residue of formula (A) ##STR2## The compounds are characterized by having cis-stereochemistry between the groups 8--F and 9--OH. Their preparation and pharmaceutical compositions containing them are also described.

Abstract: New 8-fluoroanthracycline derivatives of formula I possessing antitumoral properties are described, together with their preparation and pharmaceutical compositions containing them.

Abstract: The present invention is referred to compounds of general formula (I) and (II), respectively ##STR1## their pharmaceutically acceptable salts, the process for their preparation, and the pharmaceutical compositions containing them.

Abstract: A description is given of tachykinin receptor antagonists having general formula (I) ##STR1## their preparation and use in pharmaceutical formulations.

Abstract: The present invention refers to tachykinins antagonists of general formula (I) ##STR1## their preparation and pharmaceutical compositions containing them.

Abstract: The present invention relates to Distamycin compounds of formula (I), methods of use and their pharmaceutical compositions.

Abstract: A description is given of tachyquinine antagonists having general formula (I) ##STR1## their preparation and use in pharmaceutical formulations.

Abstract: This invention relates to polyaminopyrrolecarboxyamide derivatives of general formula (I) and their pharmaceutically acceptable salts, in which A represents a chemical bond or an aromatic or heteroaromatic radical, and:if A is a chemical bond, R is hydrogen, alkyl, dialkylaminoalkyl, alkenyl, cycloalkyl, arylalkyl, arylalkenyl, haloalkyl, or an aromatic or heteroaromatic radical;whereas if A is an aromatic or heteroaromatic radical, R is nitro, amino or formylamino;n is 0 or a whole number between 1 and 4;Z is an alkylene or aromatic radical.

Abstract: The present invention relates to a new process for the preparation of Erbstatin and Erbstatin analogs, which can be represented by the following formula (I) ##STR1## wherein R is hydrogen, a lower alkyl or a lower alkanoyl group;n is an integer of 1 to 3;A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --;R.sub.1 is hydrogen or a lower alkyl group, andR.sub.2 is a hydrogen or halogen atom.